

Steinbjörn Hansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/311748/publications.pdf>

Version: 2024-02-01

44
papers

6,268
citations

236925

25
h-index

243625

44
g-index

44
all docs

44
docs citations

44
times ranked

8684
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. <i>Scientific Reports</i> , 2021, 11, 17918.	3.3	22
2	Prognostic value of O ⁶ -methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 172-184.	3.2	34
3	Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 185-206.	3.2	178
4	Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014. <i>Journal of Neuro-Oncology</i> , 2018, 139, 479-489.	2.9	39
5	Male coping through a long-term cancer trajectory. Secondary outcomes from a RTC examining the effect of a multidisciplinary rehabilitation program (RePCa) among radiated men with prostate cancer. <i>Acta Oncologica</i> , 2017, 56, 254-261.	1.8	11
6	Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. <i>Journal of Neuro-Oncology</i> , 2017, 135, 571-579.	2.9	185
7	Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer. <i>Scandinavian Journal of Urology</i> , 2017, 51, 457-463.	1.0	8
8	Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. <i>Acta Oncologica</i> , 2017, 56, 1776-1785.	1.8	17
9	Expression and prognostic value of JAM-A in gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 135, 107-117.	2.9	15
10	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3189-3197.	1.6	251
11	APNG as a prognostic marker in patients with glioblastoma. <i>PLoS ONE</i> , 2017, 12, e0178693.	2.5	11
12	Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. <i>PLoS ONE</i> , 2017, 12, e0182954.	2.5	61
13	The Danish Neuro-Oncology Registry. <i>Clinical Epidemiology</i> , 2016, Volume 8, 629-632.	3.0	7
14	Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. <i>PLoS ONE</i> , 2016, 11, e0155106.	2.5	23
15	The Danish Prostate Cancer Database. <i>Clinical Epidemiology</i> , 2016, Volume 8, 649-653.	3.0	11
16	Salvage radiation therapy following radical prostatectomy. A national Danish study. <i>Acta Oncologica</i> , 2016, 55, 598-603.	1.8	17
17	The Danish Neuro-Oncology Registry: establishment, completeness and validity. <i>BMC Research Notes</i> , 2016, 9, 425.	1.4	11
18	Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. <i>Acta Oncologica</i> , 2016, 55, 418-422.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Expression and prognostic value of the WEE1 kinase in gliomas. <i>Journal of Neuro-Oncology</i> , 2016, 127, 381-389.	2.9	48
20	Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015, 115, 744-752.	2.5	47
21	High levels of c-Met is associated with poor prognosis in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 122, 517-527.	2.9	62
22	Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. <i>Acta Oncologica</i> , 2014, 53, 939-944.	1.8	29
23	Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls. <i>CNS Oncology</i> , 2014, 3, 287-298.	3.0	10
24	Statin use and survival following glioblastoma multiforme. <i>Cancer Epidemiology</i> , 2014, 38, 722-727.	1.9	57
25	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 700-712.	10.7	1,280
26	A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). <i>Journal of Neuro-Oncology</i> , 2013, 114, 309-317.	2.9	33
27	The effects of multidisciplinary rehabilitation: RePCA—a randomised study among primary prostate cancer patients. <i>British Journal of Cancer</i> , 2013, 109, 3005-3013.	6.4	41
28	MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. <i>Journal of Neuro-Oncology</i> , 2013, 111, 71-81.	2.9	87
29	Prognostic value of Musashi-1 in gliomas. <i>Journal of Neuro-Oncology</i> , 2013, 115, 453-461.	2.9	46
30	Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. <i>Annals of Oncology</i> , 2013, 24, 2402-2408.	1.2	126
31	Embracing life after prostate cancer. A male perspective on treatment and rehabilitation. <i>European Journal of Cancer Care</i> , 2013, 22, 549-558.	1.5	22
32	Living alone, obesity and smoking: Important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer. <i>Acta Oncologica</i> , 2012, 51, 722-729.	1.8	47
33	A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. <i>Acta Oncologica</i> , 2012, 51, 797-804.	1.8	55
34	Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 295-301.	2.3	9
35	Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. <i>Neuro-Oncology</i> , 2010, 12, 508-16.	1.2	149
36	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. <i>Lancet</i> , The, 2010, 376, 1147-1154.	13.7	2,857

#	ARTICLE	IF	CITATIONS
37	Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. <i>European Journal of Endocrinology</i> , 2009, 161, 631-637.	3.7	108
38	Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. <i>Journal of Neuro-Oncology</i> , 2009, 95, 117-128.	2.9	72
39	Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. <i>British Journal of Cancer</i> , 2003, 88, 102-108.	6.4	31
40	Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. <i>British Journal of Cancer</i> , 1998, 77, 932-940.	6.4	97
41	Estimates of the sources of variation (variance components) of bioelectric impedance and anthropometric measurements in an epidemiological case-control study of breast cancer. <i>European Journal of Clinical Nutrition</i> , 1997, 51, 764-770.	2.9	11
42	The non-invasive acetylene rebreathing method for estimation of cardiac output: influence of breath-by-breath variation. <i>Clinical Physiology</i> , 1997, 17, 193-202.	0.7	6
43	Precision and accuracy of a noninvasive inert gas washin method for determination of cardiac output in men. <i>Journal of Applied Physiology</i> , 1994, 76, 1560-1565.	2.5	13
44	Repeatability of the acetylene rebreathing method in measuring cardiac output: influence of acetylene concentration. <i>Acta Anaesthesiologica Scandinavica</i> , 1990, 34, 354-357.	1.6	13